These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30504321)

  • 1. The MDS genomics-prognosis symbiosis.
    Nazha A
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):270-276. PubMed ID: 30504321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does mutational burden add to other prognostic factors in MDS?
    Nazha A
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101098. PubMed ID: 31779975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDS prognostic scoring systems – past, present, and future.
    Jonas BA; Greenberg PL
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):3-13. PubMed ID: 25659725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When to use which molecular prognostic scoring system in the management of patients with MDS?
    Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
    Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
    Vidal V; Robert G; Goursaud L; Durand L; Ginet C; Karsenti JM; Luciano F; Gastaud L; Garnier G; Braun T; Hirsch P; Raffoux E; Nloga AM; Padua RA; Dombret H; Rohrlich P; Ades L; Chomienne C; Auberger P; Fenaux P; Cluzeau T
    Oncotarget; 2017 Jul; 8(29):47103-47109. PubMed ID: 28514758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
    Scalzulli E; Pepe S; Colafigli G; Breccia M
    Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
    Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome.
    Iacobucci I; Mullighan CG
    Curr Opin Hematol; 2021 Mar; 28(2):101-109. PubMed ID: 33427759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Bennett JM
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
    Minetto P; Guolo F; Clavio M; De Astis E; Colombo N; Grasso R; Fugazza G; Sessarego M; Lemoli RM; Gobbi M; Miglino M
    Leuk Res; 2015 Aug; 39(8):866-73. PubMed ID: 26012361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes.
    Kelaidi C; Tzannou I; Baltadakis I; Batsis I; Mallouri D; Spyridonidis A; Gigantes S; Tsirigotis P; Apostolidis I; Athanasiadou A; Manola K; Anagnostopoulos A; Harhalakis N; Sakellari I; Karakasis D
    Bone Marrow Transplant; 2014 Aug; 49(8):1022-8. PubMed ID: 24797183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
    DeZern AE; Greenberg PL
    Blood; 2023 Dec; 142(26):2258-2267. PubMed ID: 37562001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
    Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
    Nazha A; Sekeres MA; Gore SD; Zeidan AM
    Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.